Compare GHG & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | PROF |
|---|---|---|
| Founded | 2004 | N/A |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 243.2M |
| IPO Year | 2017 | 2017 |
| Metric | GHG | PROF |
|---|---|---|
| Price | $1.14 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 22.6K | ★ 70.3K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $19.02 | $92.40 |
| Revenue Next Year | $8.26 | $64.10 |
| P/E Ratio | ★ $5.76 | $35.42 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $1.14 | $3.92 |
| 52 Week High | $2.78 | $8.95 |
| Indicator | GHG | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 51.41 |
| Support Level | $1.16 | $5.81 |
| Resistance Level | $1.34 | $7.07 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 15.38 | 25.57 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.